📰 Alacyclovir News
Page 3 - Alacyclovir News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alacyclovir. Real-time updates on events, politics, business and more.
August 29, 2023
The move is important because, previously, some people with liver disease had limited treatment options for severe cases of COVID-19.
August 4, 2023
Gilead Sciences reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs.
July 7, 2023
Bulevirtide, an investigational, first-in-class hepatitis delta virus entry-inhibitor, significantly reduced viral load and normalized liver enzymes in patients.
June 9, 2023
"The take-home finding is that herpes zoster incidence is high among people with MS overall."
May 5, 2023
"Although the details are not important for prescribing internists, having a basic understanding of the mechanism of action can help [us] better understand for which patients the drugs are indicated."
April 28, 2023
Dublin, April 28, 2023 (GLOBE NEWSWIRE) -- The "Global Herpes Simplex Virus Treatment Market Size, Share & Industry Trends Analysis Report by Drug...
April 14, 2023
First Nations groups collaborated in a population-based study that identified shortcomings in care for patients with hepatitis C in Ontario.
April 11, 2023
When researchers compared patients who met treatment criteria, treatment initiation was similar across races and socioeconomic status. But that finding raises other questions.
April 5, 2023
Gilead Sciences on Tuesday unveiled data from the first human study of its experimental oral COVID-19 antiviral, saying the results in healthy volunteers cleared the way for two large Phase III trials.
April 1, 2023
The viral inhibitor also appears effective against all coronavirus variants of concern, neutralizing even the Omicron variants BA.5, XBB, and BQ.1.1 in laboratory and mice studies.